Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)

BACKGROUND: Sotrovimab, a monoclonal antibody with efficacy against SARS-CoV-2 including certain Omicron variants, has been used in treatment of mild-moderate COVID-19. Limited data exists regarding its use in pregnant women. METHODS: Electronic medical record review of pregnant COVID-19 patients tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuan, Jessica J., Sharma, Manas, Kayani, Jehanzeb, Davis, Matthew W., McManus, Dayna, Topal, Jeffrey E., Ogbuagu, Onyema
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130811/
https://www.ncbi.nlm.nih.gov/pubmed/37101135
http://dx.doi.org/10.1186/s12879-023-08198-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130811/
https://www.ncbi.nlm.nih.gov/pubmed/37101135
http://dx.doi.org/10.1186/s12879-023-08198-9

Ejemplares similares